

Financial Tear Sheet

Corporate Profile

Accuray Incorporated is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Accuray does not assume a duty to update information on this website, except through the normal quarterly financial press releases and regulatory filings.

Stock Performance

ARAY (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$4.15
Change (%)	▲ 0.15 (3.75%)
Volume	508,347
52 Week Low	\$3.85
Market Cap	\$344,454,009
Rolling EPS	-0.39
PE Ratio	N/A
Shares Outstanding	83,000,966

Data as of May 26, 2017 4:00 p.m. ET



Press Releases

May 24, 2017 - 7:31 a.m.

Accuray Appoints Stan Gee VP of Revenue
Management

There are currently no events scheduled.





May 11, 2017 - 7:40 a.m.

New Data Reinforce Benefits of TomoTherapy®
Platform for Mainstream Radiation Therapy
Treatment Indications

May 11, 2017 - 7:31 a.m.

New Data Presented at ESTRO 36 Reinforce
Unmatched Versatility and Precision of the
CyberKnife® System

SEC Filings

Filing Date	Form	
May 25, 2017	3	
May 25, 2017	3	
May 5, 2017	10-Q	
May 2, 2017	4	

Corporate Governance

Joshua H. Levine	President and Chief Executive Officer
LIONEL HADJADJEBBA	SENIOR VICE PRESIDENT, CHIEF COMMERCIAL OFFICER
Kelly J. Londy	Executive Vice President, Chief Operating Officer
Kevin Waters	Senior Vice President, Chief Financial Officer
Darl S. Moreland	Senior Vice President, Regulatory, Quality and Compliance
Alaleh Nouri	Senior Vice President, General Counsel and Corporate Secretary
Andy Kirkpatrick	Senior Vice President, Global Operations and Corporate Development

Data provided by Nasdaq. Minimum 15 minutes delayed.

© 2007 - 2017 Accuray Incorporated. All Rights Reserved.